ReviewJACS Au2026
Plasmonic Nanoparticle-Metal-Organic Framework Hybrid Nanostructures for Biomedical Applications: From Design to Function.
Review in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmonic nanoparticle-metal-organic framework (plasmonic NP-MOF) hybrid nanostructures have emerged as distinctive platforms that synergistically combine the physical, chemical, and biological properties and functions of plasmonic nanoparticles and MOFs, enabling biomedical capabilities inaccessible to either component alone. This Perspective focuses on a central design-to-function relationship: the structural paradigm between the plasmonic nanoparticle and the MOF governs how the properties of the two components complement one another and interact synergistically. We consider four principal configurations: plasmonic NPs embedded within MOF pores, plasmonic NPs decorate the MOF exterior, and a plasmonic NP serves as the core of a plasmonic@MOF core-shell structure or forms the shell of a MOF@plasmonic NP core-shell structure. Each configuration offers distinct functional advantages suited to specific biomedical applications. Here, we first review the synthetic strategies and formation mechanisms underlying these four hybrid nanostructures. We then examine how these structure-dependent properties manifest across three major biomedical application areas: biosensing, drug delivery, and therapeutic applications. Finally, we identify the synthetic limitations constraining structural precision, reproducibility, and material versatility, as well as translational barriers that must be addressed to advance plasmonic nanoparticle-MOF hybrids toward robust and clinically relevant biomedical probes and platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.